XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at 12 months in the vilamakitug arm, surpassing the pre-specified efficacy threshold. Notably, patients with right-sided colon tumors experienced a significant survival benefit. The treatment was well tolerated and demonstrated potential for further clinical development targeting this aggressive cancer subtype.
XBiotech's phase II trial results in metastatic colorectal cancer provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 05:21 WIB: Among 150 priced US health-sector stocks, 81 rose and 67 fell. Notable movers include SELLAS Life Sciences Group Inc. (SLS) at USD 10.48 with a +5.01% change and a typical hold time of 5 days, Hinge Health Inc. (HNGE) at USD 103.96 up +4.84%, and Relay Therapeutics Inc. (RLAY) at USD 17.06 up +4.79%, with a typical hold time of 10 days.
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
